[ET Net News Agency, 16 September 2021] HEPALINK (09989) fell 2.03% to HK$8.7.
It hits an intra-day low of HK$8.7, hitting a historical low, and an intra-day high of
HK$8.86. The total shares traded was 265,000, with a value of HK$2.32m. The active
buy/sell ratio is 21:79, with net selling turnover of HK$1.33m. FUTU SEC INT'L accounts
for greatest net responsive buying turnover of HK$188,166, with volume weighted average
price of HK$8.781. CREDIT SUISSE (HK) SEC accounts for greatest net responsive selling
turnover of HK$208,849, with volume weighted average price of HK$8.819. The stock has
fallen a combined 5.95% over the past 4 consecutive trading days.
The Hang Seng Index now fell 297 points, or 1.19% to 24,735; the Hang Seng China
Enterprises Index now fell 112 points, or 1.25% to 8,824; the Hang Seng TECH Index now
fell 40 points, or 0.64% to 6,257; with an overall turnover of HK$47.49b.
The SSE Composite Index now fell 3 points, or 0.1% to 3,652, with an overall turnover of
RMB282.76b.
The SZSE Component Index now fell 103 points, or 0.71% to 14,432, with an overall
turnover of RMB146.45b.
Basic Information
-------------------------------------------
Nominal 8.700 % Chg -2.03%
High 8.860 Low 8.700
Shares Tr 265,000 Turnover 2.32m
10-D SMA 9.069 %H.V 26.193
20-D SMA 9.050 VWAP 8.758
50-D SMA 9.492 RSI14 34.303
-------------------------------------------
Status: Hitting a historical low, active buy/sell ratio is 21:79, with net selling
turnover of HK$1.33m, falling a combined 5.95% over the past 4 consecutive
trading days
Table: Performance of stocks in the same sector or of relevance
Stock (Code) Price(HK$) Change(%)
-------------------------------------------------
HEPALINK (09989) 8.70 -2.03
SIHUAN PHARM (00460) 1.99 -3.86
CMS (00867) 14.10 -3.03
CSPC PHARMA (01093) 9.21 -3.26
SINO BIOPHARM (01177) 6.17 -4.04
FOSUN PHARMA (02196) 44.50 -1.66
WUXI APPTEC (02359) 165.40 -1.61
CHINARES PHARMA (03320) 3.91 -2.25
HANSOH PHARMA (03692) 18.34 -7.47
PHARMARON (03759) 174.60 -3.80
-------------------------------------------------
(ed)